Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 12: 732530, 2021.
Article in English | MEDLINE | ID: mdl-34925315

ABSTRACT

A numerous number of positive and negative signals via various molecules modulate T-cell activation. Within the various transmembrane proteins, SIRPγ is of interest since it is not expressed in rodents. SIRPγ interaction with CD47 is reevaluated in this study. Indeed, we show that the anti-SIRPγ mAb clone LSB2.20 previously used by others has not been appropriately characterized. We reveal that the anti-SIRPα clone KWAR23 is a Pan anti-SIRP mAb which efficiently blocks SIRPα and SIRPγ interactions with CD47. We show that SIRPγ expression on T cells varies with their differentiation and while being expressed on Tregs, is not implicated in their suppressive functions. SIRPγ spatial reorganization at the immune synapse is independent of its interaction with CD47. In vitro SIRPα-γ/CD47 blockade with KWAR23 impairs IFN-γ secretion by chronically activated T cells. In vivo in a xeno-GvHD model in NSG mice, the SIRPγ/CD47 blockade with the KWAR23 significantly delays the onset of the xeno-GvHD and deeply impairs human chimerism. In conclusion, we have shown that T-cell interaction with CD47 is of importance notably in chronic stimulation.


Subject(s)
Antigens, Differentiation/metabolism , CD47 Antigen/metabolism , Graft vs Host Disease/immunology , Lymphocyte Activation/drug effects , Muromonab-CD3/administration & dosage , Receptors, Immunologic/metabolism , Signal Transduction/drug effects , T-Lymphocytes/immunology , Animals , Antigens, Differentiation/genetics , Antigens, Differentiation/immunology , Blood Donors , CD47 Antigen/genetics , Disease Models, Animal , Female , Gene Knock-In Techniques , Gene Knockout Techniques , Healthy Volunteers , Heterografts , Humans , Jurkat Cells , Lymphocyte Activation/genetics , Male , Mice , Muromonab-CD3/immunology , Receptors, Immunologic/genetics , Receptors, Immunologic/immunology , Signal Transduction/genetics
2.
PLoS One ; 13(2): e0192602, 2018.
Article in English | MEDLINE | ID: mdl-29447206

ABSTRACT

Anti-HCMV treatments used in immunosuppressed patients reduce viral replication, but resistant viral strains can emerge. Moreover, these drugs do not target latently infected cells. We designed two anti-viral CRISPR/Cas9 strategies to target the UL122/123 gene, a key regulator of lytic replication and reactivation from latency. The singleplex strategy contains one gRNA to target the start codon. The multiplex strategy contains three gRNAs to excise the complete UL122/123 gene. Primary fibroblasts and U-251 MG cells were transduced with lentiviral vectors encoding Cas9 and one or three gRNAs. Both strategies induced mutations in the target gene and a concomitant reduction of immediate early (IE) protein expression in primary fibroblasts. Further detailed analysis in U-251 MG cells showed that the singleplex strategy induced 50% of indels in the viral genome, leading to a reduction in IE protein expression. The multiplex strategy excised the IE gene in 90% of all viral genomes and thus led to the inhibition of IE protein expression. Consequently, viral genome replication and late protein expression were reduced by 90%. Finally, the production of new viral particles was nearly abrogated. In conclusion, the multiplex anti-UL122/123 CRISPR/Cas9 system can target the viral genome efficiently enough to significantly prevent viral replication.


Subject(s)
Clustered Regularly Interspaced Short Palindromic Repeats , Cytomegalovirus/physiology , Virus Replication , Cell Line , Cytomegalovirus/genetics , Flow Cytometry , Humans , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...